<?xml version="1.0" encoding="UTF-8"?>
<p id="Par32">Similarly, COVA1-18 and COVA2-15 were identified from convalescent patients by using SARS-CoV-2 S protein as antigen. Both NMAbs targeted the RBD of SARS-CoV-2 S protein.
 <sup>
  <xref ref-type="bibr" rid="CR40">40</xref>
 </sup> These mAbs showed neutralization activity against the pseudovirus of SARS-CoV-2 with an IC
 <sub>50</sub> value of 8 ng/ml and potently inhibited live SARS-CoV-2 infection with IC
 <sub>50</sub> values of 7 and 9 ng/ml, respectively.
</p>
